{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:18:41Z","timestamp":1788578321766,"version":"build-2803163510"},"reference-count":37,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T00:00:00Z","timestamp":1423440000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The recent outbreak of the Ebola virus in West Africa has highlighted the clear shortage of broad-spectrum antiviral drugs for emerging viruses. There are numerous FDA approved drugs and other small molecules described in the literature that could be further evaluated for their potential as antiviral compounds. These molecules are in addition to the few new antivirals that have been tested in Ebola patients but were not originally developed against the Ebola virus, and may play an important role as we await an effective vaccine. The balance between using FDA approved drugs versus novel antivirals with minimal safety and no efficacy data in humans should be considered. We have evaluated 55 molecules from the perspective of an experienced medicinal chemist as well as using simple molecular properties and have highlighted 16 compounds that have desirable qualities as well as those that may be less desirable. In addition we propose that a collaborative database for sharing such published and novel information on small molecules is needed for the research community studying the Ebola virus.<\/ns4:p>","DOI":"10.12688\/f1000research.6120.1","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T10:16:18Z","timestamp":1423476978000},"page":"38","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Small molecules with antiviral activity against the Ebola virus"],"prefix":"10.12688","volume":"4","author":[{"given":"Nadia","family":"Litterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lipinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5790","authenticated-orcid":false,"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2015,2,9]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"29-48","DOI":"10.1039\/c4np00085d","article-title":"Antiviral drug discovery: broad-spectrum drugs from nature.","volume":"32","author":"J Martinez","year":"2015","journal-title":"Nat Prod Rep."},{"key":"ref-2","article-title":"World Health Organization media center","year":"2014"},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"217-24","DOI":"10.1016\/j.coviro.2013.03.001","article-title":"Intervention strategies for emerging viruses: use of antivirals.","volume":"3","author":"Y Debing","year":"2013","journal-title":"Curr Opin Virol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"e1752","DOI":"10.1371\/journal.pntd.0001752","article-title":"Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials.","volume":"6","author":"C Simmons","year":"2012","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"209-18","DOI":"10.1038\/nrmicro775","article-title":"SARS--beginning to understand a new virus.","volume":"1","author":"K Stadler","year":"2003","journal-title":"Nat Rev Microbiol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"58-62","DOI":"10.1016\/j.coviro.2014.01.010","article-title":"MERS: emergence of a novel human coronavirus.","volume":"5","author":"V Raj","year":"2014","journal-title":"Curr Opin Virol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"13-25","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs.","volume":"1","author":"E De Clercq","year":"2002","journal-title":"Nat Rev Drug Discov."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"704-20","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies.","volume":"2","author":"E De Clercq","year":"2004","journal-title":"Nat Rev Microbiol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1-10","DOI":"10.1016\/j.bcp.2014.11.008","article-title":"Ebola virus (EBOV) infection: Therapeutic strategies.","volume":"93","author":"E De Clercq","year":"2015","journal-title":"Biochem Pharmacol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"2045-58","DOI":"10.1016\/j.jmb.2014.01.010","article-title":"In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity.","volume":"426","author":"C Brown","year":"2014","journal-title":"J Mol Biol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"7294-306","DOI":"10.1128\/JVI.00591-14","article-title":"Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.","volume":"88","author":"Z Han","year":"2014","journal-title":"J Virol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1157-69","DOI":"10.1021\/jm100938u","article-title":"A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.","volume":"54","author":"I Opsenica","year":"2011","journal-title":"J Med Chem."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"102-9","DOI":"10.1016\/j.antiviral.2014.04.014","article-title":"Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.","volume":"107","author":"J Johnson","year":"2014","journal-title":"Antiviral Res."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"190ra79","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.","volume":"5","author":"L Johansen","year":"2013","journal-title":"Sci Transl Med."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"e60579","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.","volume":"8","author":"P Madrid","year":"2013","journal-title":"PLoS One."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2123-31","DOI":"10.1093\/jac\/dku091","article-title":"The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.","volume":"69","author":"G Gehring","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"ref-17","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.5741.1","article-title":"A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.","volume":"3","author":"S Ekins","year":"2014","journal-title":"F1000Res."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"897-905","DOI":"10.1124\/dmd.112.050054","article-title":"Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).","volume":"41","author":"F Kazmi,","year":"2013","journal-title":"Drug Metab Dispos."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"715-23","DOI":"10.1016\/j.tiv.2010.12.010","article-title":"A high content screening assay for identifying lysosomotropic compounds.","volume":"25","author":"S Nadanaciva","year":"2011","journal-title":"Toxicol In Vitro."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"17-21","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.","volume":"105","author":"L Oestereich","year":"2014","journal-title":"Antiviral Res."},{"key":"ref-21","article-title":"French nurse cured of Ebola contracted in Liberia","year":"2014"},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1171-8","DOI":"10.1586\/14787210.2014.948847","article-title":"Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.","volume":"12","author":"D Florescu","year":"2014","journal-title":"Expert Rev Anti Infect Ther."},{"key":"ref-23","article-title":"Chimerix's Brincidofovir Has in Vitro Activity Against Ebola","year":"2014"},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"196-206","DOI":"10.1177\/1060028014561227","article-title":"Potential and Emerging Treatment Options for Ebola Virus Disease.","volume":"49","author":"B Bishop","year":"2015","journal-title":"Ann Pharmacother."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"402-5","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.","volume":"508","author":"T Warren","year":"2014","journal-title":"Nature."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"2996-3004","DOI":"10.1021\/ci500445u","article-title":"Computational Prediction and Validation of an Expert\u2019s Evaluation of Chemical Probes.","volume":"54","author":"N Litterman","year":"2014","journal-title":"J Chem Inf Model."},{"key":"ref-27","doi-asserted-by":"publisher","DOI":"10.1021\/jm5011308","article-title":"Parallel Worlds of Public or Commercial Bioactive Chemistry Data.","author":"C Lipinski","year":"2014","journal-title":"J Med Chem."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"2719-2740","DOI":"10.1021\/jm901137j","article-title":"New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays.","volume":"53","author":"J Baell","year":"2010","journal-title":"J Med Chem."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"481-3","DOI":"10.1038\/513481a","article-title":"Chemistry: Chemical con artists foil drug discovery.","volume":"513","author":"J Baell","year":"2014","journal-title":"Nature."},{"key":"ref-30","doi-asserted-by":"crossref","first-page":"1-18","DOI":"10.1273\/cbij.13.1","article-title":"Cheminformatics workflows using mobile apps.","volume":"13","author":"A Clark","year":"2013","journal-title":"Chem-Bio Informatics J."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"3157-62","DOI":"10.1073\/pnas.0909587107","article-title":"A broad-spectrum antiviral targeting entry of enveloped viruses.","volume":"107","author":"M Wolf","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"261-70","DOI":"10.1016\/j.drudis.2008.11.015","article-title":"Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery.","volume":"14","author":"M Hohman","year":"2009","journal-title":"Drug Discov Today."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"414-35","DOI":"10.1007\/s11095-013-1172-7","article-title":"Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.","volume":"31","author":"S Ekins","year":"2014","journal-title":"Pharm Res."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"370-378","DOI":"10.1016\/j.chembiol.2013.01.011","article-title":"Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery.","volume":"20","author":"S Ekins","year":"2013","journal-title":"Chem Biol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.12688\/f1000research.6110.1","article-title":"Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection.","volume":"4","author":"V Veljkovic","year":"2015","journal-title":"F1000Res."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.","volume":"3","author":"J Kouznetsova","year":"2014","journal-title":"Emerging Microbes Infect."},{"key":"ref-37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.12688\/f1000research.6085.2","article-title":"Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.","volume":"4","author":"J Long","year":"2015","journal-title":"F1000Res."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/4-38\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/4-38\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/4-38\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T08:10:34Z","timestamp":1543997434000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/4-38\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,9]]},"references-count":37,"URL":"https:\/\/doi.org\/10.12688\/f1000research.6120.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.6555.r7713","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.6555.r7611","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.6555.r7611","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.6555.r7713","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,9]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/4-38\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.6555.r7611, John A. Lowe III, JL3Pharma LLC, Stonington, CT, USA, 11 Feb 2015, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/4-38\/v1#referee-response-7611","order":0,"name":"referee-response-7611","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Sean Ekins<\/b>; \n<i>Posted: 02 Mar 2015<\/i>; Thank you for your review and comments!","URL":"https:\/\/f1000research.com\/articles\/4-38\/v1#referee-comment-1249","order":1,"name":"referee-comment-1249","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.6555.r7713, Paul S Anderson, Independent Pharmaceuticals Professional, Lansdale, PA, 19446, USA, 19 Feb 2015, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/4-38\/v1#referee-response-7713","order":2,"name":"referee-response-7713","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>Sean Ekins<\/b>; \n<i>Posted: 02 Mar 2015<\/i>; Thank you for your positive review comments.","URL":"https:\/\/f1000research.com\/articles\/4-38\/v1#referee-comment-1250","order":3,"name":"referee-comment-1250","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}